How much weight loss does Tesofensine cause?

In the Phase 2 TIPO-1 trial, Tesofensine 0.5mg daily produced 10.6% weight loss at 24 weeks vs 2.2% placebo. The 1.0mg dose caused 12.8% loss but with more side effects.

What are Tesofensine's side effects?

Dry mouth (~40%), nausea (~30%), constipation, insomnia, elevated heart rate (+5 bpm), and elevated systolic blood pressure (+2-3 mmHg. The cardiovascular effects halted Phase 3 development.

Is Tesofensine the same as an amphetamine?

No, but mechanistically similar in CNS action. Tesofensine inhibits reuptake of dopamine, noradrenaline, and serotonin (triple reuptake inhibitor). It is not a releasing agent like amphetamine and has lower abuse potential in preclinical models.

Does Tirzepatide cause heart rate elevation?

Yes — Tirzepatide (like all GLP-1 agonists) increases resting heart rate by an average of 4-5 bpm. This is a class effect of GLP-1 receptor agonism, separate from Tesofensine's norepinephrine-mediated elevation.

Can Tesofensine be used with SSRIs?

No. Tesofensine inhibits serotonin reuptake; combining it with SSRIs or SNRIs creates significant serotonin syndrome risk. This is a firm contraindication.

Which causes more muscle loss — Tesofensine or Tirzepatide?

Both cause muscle loss as part of rapid weight loss. Tirzepatide has more data — preserving ~70% lean mass per kg lost in SURMOUNT trials when combined with adequate protein intake. Tesofensine muscle data is limited.

Is Tesofensine available to buy?

Tesofensine is available from some research chemical vendors as an oral formulation. Legal status varies by jurisdiction. It is not approved for human use in any country.

Tesofensine vs Tirzepatide: Dosing, Half-Life, Side Effects + Which to Choose (2026) | PeptiDex

Editor's Note

Tesofensine data is limited to Phase 2 trials (2008-2012). No Phase 3 RCT has been completed. Long-term safety data is insufficient. This comparison reflects available preclinical and Phase 2 evidence only.

Quick Verdict

Tirzepatide is the evidence-backed, FDA-approved standard for weight loss. Tesofensine offers an alternative CNS mechanism for GLP-1 non-responders — but lacks Phase 3 data. Research context: these should not be stacked due to cardiovascular risk.

Side-by-Side Analysis

Dimension	Tesofensine	Tirzepatide
Mechanism	Triple monoamine reuptake inhibitor (inhibits reuptake of serotonin, noradrenaline, and dopamine).	Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Primary Benefits	Extreme fat loss and appetite suppression without GLP-1 side effects	Weight loss, body recomposition, glycemic control
Typical Dose	250–500mcg	2500–2500mcg
Route	Oral	SubQ
Frequency	Daily	1x/wk
Half-Life	216 hours	120 hours
FDA Status	Research Only	Approved
Evidence Grade	strong	very-strong
Key Studies	20+ indexed	20+ indexed
Lowest Price	—	$69.99 / 5mg via Amino Club

Which one should you choose?

Tirzepatide is the more established, better-characterized weight loss agent with superior clinical data; Tesofensine offers a completely different mechanism (CNS stimulation vs. gut hormone modulation) that may work where GLP-1s plateau. Tirzepatide reduces appetite via gut hormone mimicry. Tesofensine reduces appetite centrally via dopamine/norepinephrine/serotonin, while also increasing basal metabolic rate through thermogenesis. Choose Tirzepatide for proven, guideline-supported metabolic intervention. Choose Tesofensine if GLP-1s have failed or caused unacceptable side effects.

Who Should Choose Tesofensine?

Choose Tesofensine (research context) if:

GLP-1 agonists have failed or caused intolerable GI side effects
You are researching CNS-mediated appetite suppression
Subject has preserved renal/cardiac function (SNDRI safety prerequisite)
Researching thermogenic mechanisms alongside appetite suppression

Who Should Choose Tirzepatide?

Choose Tirzepatide if:

You want the most evidence-supported weight loss intervention
Subject has comorbid T2DM or insulin resistance
GI side effects of semaglutide have been an issue (Tirzepatide is often better tolerated)
Long-term cardiac safety profile is a priority

Can you stack Tesofensine + Tirzepatide?

Do NOT stack Tesofensine + Tirzepatide. Tesofensine raises blood pressure and heart rate via norepinephrine/dopamine mechanisms. Combined with GLP-1-mediated heart rate changes, the cardiovascular risk is unacceptable in research settings.

Vendor Pricing

· Affiliate links · Prices verified 2026

Tesofensine

Pricing coming soon

Tirzepatide

2 vendors

Amino Club Best Value

5mg vial · $14.00/mg

$69.99Buy

Limitless Life

5mg vial · $16.00/mg

$80.00Buy

Full vendor comparison for Tirzepatide

Affiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.

Frequently Asked Questions

No. Tesofensine completed Phase 2 trials showing ~10% weight loss at 24 weeks (PMID: 18950803). Phase 3 development was not pursued due to cardiovascular safety signals (elevated heart rate and blood pressure).

Related Comparisons

Weight Loss

Deep Dive Profiles

Tesofensine Research Profile Tirzepatide Research Profile

⚠ Educational only · Not medical advice · Research compounds not approved by FDA for human consumption

Tesofensine vs Tirzepatide.